Koers Tiziana Life Sciences PLC London S.E.
Aandelen
GB00B28XMY25
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- GBX | - |
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 56,17 mln. 51,8 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -15 mln. -13,83 mln. | Nettowinst (verlies) 2023 | -17 mln. -15,68 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 17,76 mln. 16,37 mln. | Nettoliquiditeiten 2023 | 936K 863K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-3,95
x | K/w-verhouding 2023 |
-3,29
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 32,75% |
Recentste transcriptie over Tiziana Life Sciences PLC
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 11-02-98 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | - |
Vaseem Palejwala
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 01-07-20 |
Willy Simon
BRD | Director/Board Member | 72 | 01-11-15 |
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 11-02-98 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,36% | 58,06 mld. | |
-5,31% | 40,53 mld. | |
+37,52% | 38,99 mld. | |
+14,75% | 26,7 mld. | |
-12,56% | 26,56 mld. | |
-22,45% | 18,98 mld. | |
+0,04% | 12,17 mld. | |
+25,12% | 12 mld. | |
+26,04% | 11,92 mld. |
- Beurs
- Aandelen
- Koers TLSA
- Koers